AKBA
insider transactionsAkebia Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-578.8K
69.3K buy · 648.0K sell
Net value · 365d
-$814.2K
$86.6K in · $900.8K out
Sentiment · 365d
Net selling
9% buying · 91% selling
Open-market trades · 365d
16
69.3K buy · 648.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
214.4K sh
Own New
-
Buy·P
John P. Butler KEY
CEO and President
$86.6K
69.3K sh · $1.25
Own +2%
-
Sell·S
SVP, Chief Legal Officer · 10b5-1
$38.3K
27.5K sh · $1.39
Own -4%
-
Sell·S
SVP, Chief Legal Officer · 10b5-1
$35.3K
25.4K sh · $1.39
Own -4%
-
Sell·S
SVP, Chief Legal Officer · 10b5-1
$23.4K
16.8K sh · $1.39
Own -3%
-
Sell·S
SVP, Chief Accounting Officer · 10b5-1
$18.6K
13.4K sh · $1.39
Own -4%
-
Sell·S
SVP, Chief Accounting Officer · 10b5-1
$50.2K
36.1K sh · $1.39
Own -10%
-
Sell·S
Erik Ostrowski KEY
SVP, CFO, CBO & Treasurer · 10b5-1
$48.6K
35.0K sh · $1.39
Own -5%
-
Sell·S
Chief Commercial Officer · 10b5-1
$43.4K
31.2K sh · $1.39
Own -5%
-
Sell·S
Chief Commercial Officer · 10b5-1
$74.5K
53.6K sh · $1.39
Own -8%
-
Sell·S
SVP, Chief Medical Officer · 10b5-1
$28.8K
20.7K sh · $1.39
Own -2%
-
Sell·S
SVP, Chief Medical Officer · 10b5-1
$35.3K
25.4K sh · $1.39
Own -3%
-
Sell·S
SVP, Chief Medical Officer · 10b5-1
$30.0K
21.6K sh · $1.39
Own -2%
-
Sell·S
John P. Butler KEY
CEO and President · 10b5-1
$116.3K
83.7K sh · $1.39
Own -2%
-
Grant·A
John P. Butler KEY
CEO and President · 10b5-1
$247.1K
175.2K sh · $1.41
Own +5%
-
Sell·S
John P. Butler KEY
CEO and President · 10b5-1
$159.7K
114.9K sh · $1.39
Own -3%
-
Sell·S
John P. Butler KEY
CEO and President · 10b5-1
$133.5K
96.1K sh · $1.39
Own -3%
-
Sell·S
John P. Butler KEY
CEO and President · 10b5-1
$64.9K
46.7K sh · $1.39
Own -1%
-
Grant·A
SVP, Chief Legal Officer
$0
270.0K sh
Own New
-
Grant·A
SVP, Chief Legal Officer
$0
190.0K sh
Own +41%
-
Grant·A
SVP, Chief Accounting Officer
$0
119.0K sh
Own New
-
Grant·A
SVP, Chief Accounting Officer
$0
79.0K sh
Own +29%
-
Grant·A
Erik Ostrowski KEY
SVP, CFO, CBO & Treasurer
$0
320.0K sh
Own New
-
Grant·A
Erik Ostrowski KEY
SVP, CFO, CBO & Treasurer
$0
204.0K sh
Own +41%
-
Grant·A
Chief Commercial Officer
$0
320.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
204.0K sh
Own +46%
-
Grant·A
SVP, Chief Medical Officer
$0
320.0K sh
Own New
-
Grant·A
SVP, Chief Medical Officer
$0
204.0K sh
Own +25%
-
Grant·A
John P. Butler KEY
CEO and President
$0
1.1M sh
Own New
-
Grant·A
John P. Butler KEY
CEO and President
$0
743.0K sh
Own +27%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 1, 2026 | Philip J. Vickers | Grant A | 214.4K | $0 |
| Mar 4, 2026 | John P. Butler KEY | Buy P | 69.3K | $86.6K |
| Feb 2, 2026 | Carolyn M. Rucci 10b5-1 | Sell S | 27.5K | $38.3K |
| Feb 2, 2026 | Carolyn M. Rucci 10b5-1 | Sell S | 25.4K | $35.3K |
| Feb 2, 2026 | Carolyn M. Rucci 10b5-1 | Sell S | 16.8K | $23.4K |
| Feb 2, 2026 | Richard C Malabre 10b5-1 | Sell S | 13.4K | $18.6K |
| Feb 2, 2026 | Richard C Malabre 10b5-1 | Sell S | 36.1K | $50.2K |
| Feb 2, 2026 | Erik Ostrowski KEY 10b5-1 | Sell S | 35.0K | $48.6K |
| Feb 2, 2026 | Nicholas Grund 10b5-1 | Sell S | 31.2K | $43.4K |
| Feb 2, 2026 | Nicholas Grund 10b5-1 | Sell S | 53.6K | $74.5K |
| Feb 2, 2026 | Steven Keith Burke 10b5-1 | Sell S | 20.7K | $28.8K |
| Feb 2, 2026 | Steven Keith Burke 10b5-1 | Sell S | 25.4K | $35.3K |
| Feb 2, 2026 | Steven Keith Burke 10b5-1 | Sell S | 21.6K | $30.0K |
| Feb 2, 2026 | John P. Butler KEY 10b5-1 | Sell S | 83.7K | $116.3K |
| Feb 2, 2026 | John P. Butler KEY 10b5-1 | Grant A | 175.2K | $247.1K |
| Feb 2, 2026 | John P. Butler KEY 10b5-1 | Sell S | 114.9K | $159.7K |
| Feb 2, 2026 | John P. Butler KEY 10b5-1 | Sell S | 96.1K | $133.5K |
| Feb 2, 2026 | John P. Butler KEY 10b5-1 | Sell S | 46.7K | $64.9K |
| Jan 30, 2026 | Carolyn M. Rucci | Grant A | 270.0K | $0 |
| Jan 30, 2026 | Carolyn M. Rucci | Grant A | 190.0K | $0 |
| Jan 30, 2026 | Richard C Malabre | Grant A | 119.0K | $0 |
| Jan 30, 2026 | Richard C Malabre | Grant A | 79.0K | $0 |
| Jan 30, 2026 | Erik Ostrowski KEY | Grant A | 320.0K | $0 |
| Jan 30, 2026 | Erik Ostrowski KEY | Grant A | 204.0K | $0 |
| Jan 30, 2026 | Nicholas Grund | Grant A | 320.0K | $0 |
| Jan 30, 2026 | Nicholas Grund | Grant A | 204.0K | $0 |
| Jan 30, 2026 | Steven Keith Burke | Grant A | 320.0K | $0 |
| Jan 30, 2026 | Steven Keith Burke | Grant A | 204.0K | $0 |
| Jan 30, 2026 | John P. Butler KEY | Grant A | 1.1M | $0 |
| Jan 30, 2026 | John P. Butler KEY | Grant A | 743.0K | $0 |
About AKBA insider trading
This page tracks insider transactions for Akebia Therapeutics, Inc. (AKBA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.